Mereo BioPharma Group plc (MREO) DCF Valuation

Mereo BioPharma Group plc (MREO) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Mereo BioPharma Group plc (MREO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Mereo BioPharma Group plc? Our (MREO) DCF Calculator integrates real-world data with comprehensive customization features, allowing you to refine your forecasts and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue -.2 .5 45.9 1.9 12.6 12.7 12.8 13.0 13.1 13.2
Revenue Growth, % 0 -422.13 9178.37 -95.87 563.57 1.03 1.03 1.03 1.03 1.03
EBITDA -47.3 -47.2 -6.3 -52.9 -32.8 -5.4 -5.5 -5.5 -5.6 -5.7
EBITDA, % 30789.34 -9548.35 -13.72 -2791.11 -260.56 -42.74 -42.74 -42.74 -42.74 -42.74
Depreciation 2.5 .1 1.1 1.9 1.3 .6 .6 .6 .6 .6
Depreciation, % -1601.64 11.2 2.38 100 10.61 4.84 4.84 4.84 4.84 4.84
EBIT -49.7 -47.3 -7.4 -54.8 -34.1 -5.5 -5.6 -5.6 -5.7 -5.7
EBIT, % 32390.98 -9559.54 -16.1 -2891.11 -271.17 -43.22 -43.22 -43.22 -43.22 -43.22
Total Cash 20.6 29.5 118.7 70.9 72.3 7.6 7.7 7.8 7.9 7.9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 1.3 1.8 3.5 4.7
Account Receivables, % 0 258.52 3.89 182.35 37.32
Inventories -15.1 -5.8 -2.3 -3.4 .0 -2.7 -2.7 -2.7 -2.8 -2.8
Inventories, % 9817.21 -1180.15 -4.99 -177.31 0 -21 -21 -21 -21 -21
Accounts Payable 7.4 3.7 2.9 4.4 3.0 3.3 3.3 3.4 3.4 3.4
Accounts Payable, % -4820.1 747.09 6.27 231.72 23.46 25.95 25.95 25.95 25.95 25.95
Capital Expenditure .0 .0 -.7 .0 -.5 -.3 -.3 -.3 -.3 -.3
Capital Expenditure, % 17.21 -4.07 -1.47 -0.66357 -4.19 -2.08 -2.08 -2.08 -2.08 -2.08
Tax Rate, % 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77
EBITAT -42.1 -46.5 -6.6 -51.9 -33.5 -5.1 -5.2 -5.2 -5.3 -5.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -17.2 -60.7 -11.1 -49.1 -38.8 -3.2 -4.8 -4.9 -4.9 -5.0
WACC, % 9.13 9.15 9.13 9.14 9.15 9.14 9.14 9.14 9.14 9.14
PV UFCF
SUM PV UFCF -17.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -5
Terminal Value -71
Present Terminal Value -46
Enterprise Value -63
Net Debt -65
Equity Value 2
Diluted Shares Outstanding, MM 659
Equity Value Per Share 0.00

What You Will Get

  • Real Mereo BioPharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Mereo BioPharma’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • 🔍 Real-Life MREO Financials: Pre-filled historical and projected data for Mereo BioPharma Group plc.
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Mereo’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Mereo’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • Download: Obtain the pre-filled Excel file containing Mereo BioPharma Group plc’s (MREO) financial data.
  • Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various forecasts and instantly compare the results.
  • Make Decisions: Leverage the valuation findings to inform your investment approach.

Why Choose This Calculator for Mereo BioPharma Group plc (MREO)?

  • User-Friendly Interface: Tailored for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to suit your financial analysis.
  • Real-Time Valuation: Monitor immediate changes in Mereo BioPharma’s valuation as you tweak inputs.
  • Pre-Configured Data: Comes pre-loaded with Mereo BioPharma’s latest financial metrics for swift evaluations.
  • Relied Upon by Experts: A go-to tool for investors and analysts to make well-informed choices.

Who Should Use Mereo BioPharma Group plc (MREO)?

  • Investors: Gain insights into innovative biopharmaceutical developments to make informed investment choices.
  • Healthcare Analysts: Utilize comprehensive data to streamline research and analysis of Mereo BioPharma's market position.
  • Consultants: Easily modify reports and presentations to showcase Mereo BioPharma's strategic initiatives for clients.
  • Biotech Enthusiasts: Enhance your knowledge of drug development processes and industry trends through real-life case studies.
  • Educators and Students: Leverage this information as a valuable resource for coursework in biotechnology and finance.

What the Template Contains

  • Pre-Filled DCF Model: Mereo BioPharma Group plc’s (MREO) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital tailored for Mereo BioPharma Group plc.
  • Financial Ratios: Assess Mereo BioPharma Group plc’s profitability, leverage, and efficiency metrics.
  • Editable Inputs: Modify assumptions such as growth, margins, and CAPEX to suit your analyses.
  • Financial Statements: Annual and quarterly reports to facilitate in-depth examination.
  • Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes.

No products were found matching.